| P/E (FY) | — | Sales (TTM) | $30.9M |
| Earnings (TTM) | -$194.0M | ROE | — |
| Net Margin | −677.59% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 128.36% |
Verastem is a development-stage biopharmaceutical company developing and commercializing cancer treatments in the United States. Its product candidates are Avutometinib, an oral dual RAF/MEK inhibitor targeting the RAS/MAPK signaling pathway, and Defactinib, an oral FAK and proline-rich tyrosine kinase inhibitor for solid tumors. Its clinical studies include the RAMP 301 confirmatory trial evaluating Avutometinib and Defactinib in recurrent low-grade serous ovarian cancer and the RAMP 201 trial.
| Market Cap | $547.5M | Trading Days | 3643 |
| 52W High | 11.25 |
| 52W Low | 3.43 |
| % Off High | −44.62% |
| YTD | −19.30% | 1Y | 3.49% |
| 3Y | −39.51% | 5Y | −84.75% |
| 10Y | −65.06% | Since incept. (ann.) | −19.06% |
Product 100%
| Ann. Volatility (1Y) | 78.05% | Ann. Volatility (3Y) | 92.18% |
| Sharpe (1Y) | 0.43 | Sharpe (3Y) | 0.37 |
| Max Drawdown (1Y) | −67.97% | Max Drawdown (3Y) | −84.36% |
| Beta (3Y, vs SPY) | 0.19 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| RLMD | RELMADA THERAPEUTICS, INC. | $548.6M | — |
| SPRY | ARS Pharmaceuticals, Inc. | $563.0M | — |
| ARVN | ARVINAS, INC. | $529.1M | — |
| NVCT | Nuvectis Pharma, Inc. | $525.7M | — |
| NGNE | Neurogene Inc. | $524.9M | — |
| STTK | Shattuck Labs, Inc. | $523.0M | — |
| MPLT | MapLight Therapeutics, Inc. | $522.4M | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $575.2M | 7.2 |
| CRMD | CorMedix Inc. | $576.6M | 3.6 |
| GYRE | GYRE THERAPEUTICS, INC. | $581.2M | 58.8 |
| ALT | Altimmune, Inc. | $581.5M | — |
| TENAX THERAPEUTICS, INC. |
| $619.6M |
| — |
